CKD and CVD
Best Practices in Primary Care: Dyslipidemia and the Chronic Kidney Disease Patient
Program Overview
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among people with chronic kidney disease (CKD). While the link between CVD and CKD is apparent, primary care providers are not effectively screening and treating patients with renal disease who are at enhanced risk for cardiovascular disease and events.
Physicians should institute appropriate screening techniques into practice to be better able to identify patients with CKD, since they are at increased risk for cardiovascular events. Biomarkers of kidney function include serum creatinine and, more recently, estimated glomerular filtration rate (eGFR). These biomarkers, in addition to microalbuminuria, predict CV events and mortality.
In the general population, dyslipidemia is an established independent risk factor for cardiovascular disease. In patients with end-stage renal disease (ESRD), comorbid cardiovascular disease is present at alarming rates, and those who require hemodialysis and have cardiovascular disease continue to have a high mortality rate. Confusion over the use of lipid-lowering therapy in patients with renal failure or renal insufficiency warrants further education.
Learning Objectives
After completing this activity, the participant should be better able to
- Incorporate screening techniques into practice that identify patients with poor renal function to help prevent future cardiovascular events in these patients
- Incorporate treatment regimens that utilize evidence-based medicine resulting in reduction of cardiovascular events in patients with renal disease
Accreditation/Designation Statement
Primary Care Network is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians: Primary Care Network designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nonphysicians: All other healthcare professionals will be issued a certificate of participation.
Target Audience: This activity is targeted to all physicians and other healthcare professionals who treat patients with dyslipidemia and chronic kidney disease.
Release Date: August 2, 2011
Expiration Date: August 2, 2012
Medium: Online CME (slides/audio)
Acknowledgment of Commercial Support
This activity was developed from the live Best Practices in Primary Care™ program held in Philadelphia, Pennsylvania, on June 18, 2011, and is funded by Merck & Co, Inc.
Content for this activity developed by Vindico Medical Education. 
Method of Participation
To receive CME credit for this activity, participant must read the CME information (including the learning objectives and disclosures) and review the entire activity (slides and audio). After finishing the activity, participant must complete the post-test, evaluation, and all required personal information. To receive CME certificate, participant will need to pass the post-test with 70% accuracy or better.
Post-test and Evaluation
After completing this activity, participant should click on the Post-test button at the end of the activity. If participant receives less than 70% on the post-test, participant should return to the beginning of the activity to review the activity again. After successful completion of the post-test, participant will be asked to fill out an evaluation form and prompted to print the CME certificate. Participant should PLEASE be ready to print certificate at this time.
Statement of Disclosure and Independence
It is the policy of Primary Care Network (PCN) to ensure all its sponsored educational activities are planned, developed, and conducted in accordance with the ACCME’s Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest and Disclosure Policies that are designed to ensure that PCN sponsored educational activities are fair balanced, independent, evidence-based, and based on scientific rigor.
Primary Care Network’s Resolution of Personal Conflicts of Interest (COI) Policy aims to ensure that all conflicts are resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN sponsored activity are required to disclose to the participants any real or apparent conflict of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent external clinical reviewer and internal clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
The opinions, ideas, recommendations, and perspectives expressed in the accompanying presentations in this Primary Care Education activity are those of the activity authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations, or perspectives of their affiliated institutions, Primary Care Network, Primary Care Education, Advisory Boards and Consultants, or the activity’s commercial supporters.
Faculty and Disclosures
William James Howard, MD, MACP, FNLA
Director of the Lipid Clinic
Washington Hospital Center
Professor of Medicine
George Washington School of Medicine
Washington, DC
Dr. Howard is on the speaker’s bureau for Abbott Labs, GlaxoSmithKline, and Merck & Co; he is also a consultant and on the advisory board for Merck & Co.
Peter P. Toth, MD, PhD
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Clinical Professor
University of Illinois School of Medicine
Sterling, Illinois
Dr. Toth is on the speaker’s bureau for Abbott Labs, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck & Co, Pfizer, and Takeda. He is on the advisory board for Abbott Labs, Amgen, AstraZeneca, Genentech, and Merck & Co. Dr. Toth is also a consultant for Abbott Labs, Amylin, AstraZeneca, and Merck & Co.
Planning Committee and Disclosures
Ronald Codario, MD, FACP
Internal Medicine (ABIM Certified)
Vascular Medicine (ABVM Certified)
Clinical Lipidology (ABCL Certified)
Vascular Ultrasound (ABVM Certified)
Clinical Hypertension Specialist (ASH Certified)
Clinical Instructor in Medicine, Thomas Jefferson University Hospital
Medical Director, Vindico Medical Education
Thorofare, New Jersey
Dr. Codario has no relevant financial relationships to disclose.
Chris Rosenberg
Director of Medical Education
Vindico Medical Education
Thorofare, New Jersey
Mr. Rosenberg has no relevant financial relationships to disclose.
Bridget O’Brien
Senior Director, Educational Services
Vindico Medical Education
Thorofare, New Jersey
Ms. O’Brien has no relevant financial relationships to disclose.
William James Howard, MD, MACP, FNLA
Director of the Lipid Clinic
Washington Hospital Center
Professor of Medicine
George Washington School of Medicine
Washington, DC
Dr. Howard is on the speaker’s bureau for Abbott Labs, GlaxoSmithKline, and Merck & Co; he is also a consultant and on the advisory board for Merck & Co.
Peter P. Toth, MD, PhD
Director of Preventive Cardiology
Sterling Rock Falls Clinic, Ltd.
Clinical Professor
University of Illinois School of Medicine
Sterling, Illinois
Dr. Toth is on the speaker’s bureau for Abbott Labs, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck & Co, Pfizer, and Takeda. He is on the advisory board for Abbott Labs, Amgen, AstraZeneca, Genentech, and Merck & Co. Dr. Toth is also a consultant for Abbott Labs, Amylin, AstraZeneca, and Merck & Co.
Review Committee Disclosure
In accordance with PCN policy, all content is reviewed by external independent peer reviewers for balance, objectivity, and commercial bias. The peer reviewers, staff, and other individuals who control content have no relevant financial relationships to disclose.
Unlabeled Use Declaration
During their presentation(s), faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.
Recent Comments